Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Khalid IslamExecutive Chairman | Gain TherapeuticsGANX | Open-market buy | 24/08/09 | 24/08/12 | 50,000 sh | $1.00 | $50,000 | No record |
Gene MackCFO and Interim CEO | Gain TherapeuticsGANX | Open-market buy | 24/08/09 | 24/08/12 | 14,400 sh | $1.01 | $14,544 | No record |
Gain TherapeuticsGANX | Open-market buy | 24/07/01 | 24/07/01 | 17,000 sh2 trades | $1.22avg. | $20,670 | +6.2% | |
Jeffrey Scott RileyDirector | Gain TherapeuticsGANX | Open-market buy | 24/03/28 | 24/04/01 | 30,000 sh | $3.86 | $115,800 | No record |
Gain TherapeuticsGANX | Open-market sale | 23/12/21 | 23/12/22 | 206 sh | $2.46 | $506.76 | −3.8% | |
Gain TherapeuticsGANX | Open-market sale | 23/12/07 | 23/12/14 | 1,820 sh | $2.50 | $4,550 | −27.3% |